Genedrive PLC Total Voting Rights (0530T)
June 29 2018 - 3:36AM
UK Regulatory
TIDMGDR
RNS Number : 0530T
Genedrive PLC
29 June 2018
genedrive plc ("genedrive" or "the Company")
Total Voting Rights
In accordance with the FCA's Disclosure Guidance and
Transparency Rules, the Company wishes to notify the market of the
following:
As at 29 June 2018, the Company's issued share capital consisted
of 18,783,115 ordinary shares of 1.5 pence each ("Ordinary
Shares"), all with voting rights. No shares are currently held in
treasury. The total number of voting rights in the Company as at 29
June 2018 is therefore 18,783,115.
The above figure (18,783,115 Ordinary Shares) may be used by
shareholders as the denominator for the calculation by which they
will determine if they are required to notify their interest in, or
a change in their interest in the Company.
- Ends -
For further details please contact:
genedrive plc
David Budd: CEO +44 (0)161 989 0245
Matthew Fowler: CFO
Peel Hunt LLP
James Steel +44 (0)207 418 8900
Oliver Jackson
Consilium Strategic Communications
Chris Gardner +44 (0)203 709 5700
Matthew Neal
Laura Thornton
genedrive@consilium-comms.com
Notes to Editors
About genedrive plc
genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The Genedrive(R) HCV-ID test has received CE-IVD
Certification and has been launched in Africa and Asia Pacific.
genedrive has distribution agreements with subsidiaries of Sysmex
Corporation for the distribution of the Genedrive(R) platform in
the EMEA and SE Asia (ex India), and with ARKRAY Healthcare pvt Ltd
for the distribution of the Genedrive(R) HCV ID Kit and
Genedrive(R) platform in India.
Further details can be found at: www.genedriveplc.com and
www.genedrive.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRFKCDNFBKKAAB
(END) Dow Jones Newswires
June 29, 2018 04:36 ET (08:36 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2024 to May 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From May 2023 to May 2024
